Journal article
Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib
JA Howell, DJ Pinato, R Ramaswami, T Arizumi, C Ferrari, A Gibbin, ME Burlone, G Guaschino, P Toniutto, J Black, L Sellers, M Kudo, M Pirisi, R Sharma
Oncotarget | IMPACT JOURNALS LLC | Published : 2017
Open access
Abstract
Background and Aims: Response to sorafenib is highly variable in hepatocellular carcinoma (HCC). Baseline inflammatory parameters and treatment toxicities may improve survival prediction in patients on sorafenib therapy. Results: 442 patients with advanced stage HCC on sorafenib were recruited (follow-up 5096 person-months at risk). 88% had BCLC stage B or greater HCC and 72.3% had Child-Pugh A cirrhosis. On Cox multivariate regression, previously-treated HCC (HR 0.579, 95% CI 0.385-0.872, p=0.009), Cancer of Liver Italian Program (CLIP) score (HR 1.723, 95% CI 1.462-2.047, p < 0.0001), baseline red cell distribution width (RDW; HR 1.234, 95% CI 1.115-1.290, p < 0.0001) and neutrophil to lym..
View full abstractGrants
Awarded by Academy of Medical Sciences (AMS)
Awarded by National Institute for Health Research
Funding Acknowledgements
[ "JH is supported by a National Medical Research Council of Australia Early Career Fellowship. MP is supported by the National Institute of Health Research (NIHR), Academy of Medical Sciences (AMS) and Action Against Cancer. No specific financial support was provided for this project.", "We are grateful to Imperial College for supporting publication costs for the manuscript." ]